| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958452 | PURDUE PHARMA LP | Extruded orally administrable opioid formulations |
Nov, 2014
(9 years ago) | |
| US5965161 | PURDUE PHARMA LP | Extruded multi-particulates |
Nov, 2014
(9 years ago) | |
| US6706281 | PURDUE PHARMA LP | Melt-extrusion multiparticulates |
Nov, 2014
(9 years ago) | |
| US6335033 | PURDUE PHARMA LP | Melt-extrusion multiparticulates |
Nov, 2014
(9 years ago) | |
| US6743442 | PURDUE PHARMA LP | Melt-extruded orally administrable opioid formulations |
Nov, 2014
(9 years ago) | |
| US6589960 | PURDUE PHARMA LP | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
Palladone is owned by Purdue Pharma Lp.
Palladone contains Hydromorphone Hydrochloride.
Palladone has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Palladone are:
- US5958452
- US5965161
- US6706281
- US6335033
- US6743442
- US6589960
Palladone was authorised for market use on 24 September, 2004.
Palladone is available in capsule, extended release;oral dosage forms.
Palladone can be used as management of persistent, moderate to severe pain in patients requiring continuous, around-the-clock analgesia with a high potency opioid for an extended period of time generally weeks to months or longer.
The generics of Palladone are possible to be released after 09 November, 2020.
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 September, 2004
Treatment: Management of persistent, moderate to severe pain in patients requiring continuous, around-the-clock analgesia with a high potency opioid for an extended period of time generally weeks to months or lo...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
PALLADONE family patents
